Penny Tom Sells 65,000 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) insider Penny Tom sold 65,000 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $2.95, for a total value of $191,750.00. Following the completion of the transaction, the insider directly owned 65,000 shares in the company, valued at approximately $191,750. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Equillium Trading Up 2.1%

EQ stock opened at $2.90 on Friday. Equillium, Inc. has a 1-year low of $0.27 and a 1-year high of $3.10. The stock’s fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $1.64. The stock has a market cap of $183.37 million, a P/E ratio of -9.06 and a beta of 1.67.

Equillium (NASDAQ:EQ) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). As a group, analysts forecast that Equillium, Inc. will post -0.24 earnings per share for the current fiscal year.

Key Headlines Impacting Equillium

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP bought a new stake in Equillium in the first quarter worth $31,000. Virtu Financial LLC boosted its holdings in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after acquiring an additional 13,591 shares in the last quarter. Millennium Management LLC bought a new stake in Equillium in the third quarter worth $35,000. Persistent Asset Partners Ltd bought a new stake in Equillium in the third quarter worth $99,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Equillium in the first quarter worth $100,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Analysts Set New Price Targets

EQ has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a report on Friday, March 27th. Zacks Research upgraded Equillium to a “hold” rating in a research report on Thursday, February 26th. Stifel Nicolaus set a $5.00 price objective on Equillium in a research report on Thursday. B. Riley Financial assumed coverage on Equillium in a research report on Thursday, April 16th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Roth Mkm restated a “buy” rating and set a $12.00 price target on shares of Equillium in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.57.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.